Tirzepatide

Overview

Tirzepatide represents the first approved dual incretin receptor agonist — a class called "twincretins." By targeting both GIP and GLP-1 receptors simultaneously, it achieves synergistic effects on insulin secretion, glucagon suppression, gastric emptying, and appetite that exceed what either pathway alone can produce.

Mechanism: Dual Incretin Action

GLP-1 receptor activation (shared with semaglutide):

• Suppresses appetite via hypothalamic signaling
• Slows gastric emptying
• Stimulates glucose-dependent insulin release
• Suppresses glucagon

GIP receptor activation (unique to tirzepatide):

• Potentiates insulin secretion synergistically with GLP-1
• Acts on adipose tissue to improve fat metabolism
• May reduce GLP-1-associated nausea (GIP has opposing effects on the nausea center)
• Improves lipid metabolism and adiponectin levels

The combination produces weight loss superior to GLP-1 monotherapy at equivalent tolerability.

Clinical Trial Highlights

| Trial | Comparator | Weight Loss (Tirzepatide 15mg) | |-------|-----------|-------------------------------| | SURMOUNT-1 | Placebo | −22.5% body weight | | SURMOUNT-5 | Semaglutide 2.4mg | ~47% more weight loss | | SURPASS-2 | Semaglutide 1mg | −5.5% additional HbA1c reduction |

Titration Protocol

Standard titration to minimize GI side effects:

• Weeks 1–4: 2.5mg/week
• Weeks 5–8: 5mg/week
• Weeks 9–12: 7.5mg/week (maintenance for many)
• Weeks 13–16: 10mg/week (optional escalation)
• Weeks 17–20: 12.5mg/week
• Week 21+: 15mg/week (max dose)

Slower titration (doubling time every 8 weeks instead of 4) significantly reduces GI side effects.

vs. Semaglutide

Tirzepatide consistently outperforms semaglutide in head-to-head trials for both weight loss and glycemic control. The most direct evidence is SURPASS-2 (NEJM 2021), where all tirzepatide doses beat semaglutide 1 mg on both HbA1c and weight in type 2 diabetes. The GIP component is believed responsible for the additional efficacy. Tolerability is similar; some users report less nausea with tirzepatide, consistent with GIP's partial anti-emetic effects.

Approvals & Expanding Indications

• Mounjaro (type 2 diabetes) — FDA-approved May 2022, the first-in-class GIP/GLP-1 agonist.
• Zepbound (obesity) — FDA-approved November 2023.
• Zepbound for obstructive sleep apnea — FDA-approved December 2024, the first drug approved for moderate-to-severe OSA in adults with obesity, based on SURMOUNT-OSA (NEJM 2024), which showed large reductions in apnea-hypopnea index alongside weight loss.
• Cardiovascular outcomes (SURPASS-CVOT) — published in late 2025, tirzepatide was non-inferior to dulaglutide for major cardiovascular events in type 2 diabetes with directionally favorable mortality and kidney signals. (Reported via conference and secondary coverage; treat exact effect sizes as preliminary pending the full primary citation.)

Where It Sits: GLP-1 → Dual → Triple

| Agent | Receptors | Peak trial weight loss | |---|---|---| | Semaglutide | GLP-1 | ~15% (STEP 1) | | Tirzepatide | GIP + GLP-1 | ~21–22.5% (SURMOUNT-1) | | Retatrutide (investigational) | GIP + GLP-1 + glucagon | ~24–30% (Phase 2 / TRIUMPH topline) |

Tirzepatide is the current approved efficacy leader for weight loss. Retatrutide's triple mechanism has shown numerically greater weight loss in Phase 2, but that is a cross-trial comparison and retatrutide is not yet approved. Half-life is ~5 days, supporting once-weekly dosing.

Bottom Line

Tirzepatide is the most effective FDA-approved weight-loss and glycemic agent currently available, backed by the SURMOUNT and SURPASS programs and now expanding into sleep apnea and cardiovascular indications. Its dual-incretin mechanism set the template that the triple agonists are now building on. Standard cautions apply: dose-dependent GI effects, the rodent thyroid C-cell boxed warning, and MEN2/medullary thyroid carcinoma contraindication.